Equity Details
Price & Market Data
Price: $0.769
Daily Change: -$0.0396 / 5.15%
Daily Range: $0.692 - $0.836
Market Cap: $9,104,183
Daily Volume: 1,546
Performance Metrics
1 Week: -16.37%
1 Month: -20.28%
3 Months: -28.09%
6 Months: -59.07%
1 Year: -66.25%
YTD: -42.37%
About CytoMed Therapeutics Limited (GDTC)
Comprehensive financial data on CytoMed Therapeutics Limited (GDTC). Trading at 0.769, it has a daily change of -$0.0396 / 5.15%. Market cap: 9,104,183. Review its performance from the last week to the last year.
Company Details
Employees: 42
Sector: Health technology
Industry: Biotechnology
Country: Singapore
Details
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord derived mesenchymal stem cells for cartilage injury. It has research collaboration agreement with Sengkang General Hospital to provide CTM-MSC and its conditioned media for in vivo studies and Phase I clinical trial in Singapore. The company also has Business & Research Collaboration Agreement with SunAct Cancer Institute Private Limited to conduct clinical trials for the GMP grade CTM-GDT. CytoMed Therapeutics Limited was incorporated in 2018 and is headquartered in Singapore.